Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by puffdragon699on Mar 15, 2017 12:01pm
221 Views
Post# 25982534

RE:Aphria recalls product

RE:Aphria recalls product
premium54 wrote: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/62620r-eng.php


No biggie......

Introduction

On March 8, 2017, Aphria, a licensed producer of cannabis for medical purposes located in Ontario, began a voluntary recall of one lot of dried marijuana under a Type III recall. The affected lot number can be found below.

Reason

On March 8, 2017, Aphria initiated a voluntary Type III recall for one lot of product due to the mislabelling of the delta-9-tetrahydrocannabidiol (THC) content of the products. The THC content identified on the label was higher than the concentration present in the products. The products were mislabelled as containing 22.3% THC instead of 21.1% THC.

A Type III recall refers to a situation in which the use of, or exposure to a product, is not likely to cause any adverse health consequences.

To date, Health Canada has not received any adverse reaction reports for products sold by Aphria. However, Health Canada recommends that any individual affected by the recall immediately stop using the recalled product and to contact Aphria at the following number 1-844-427-4742.

 
Bullboard Posts